Keywords: enoxaparin, LMWHs,, COVID-19, coagulopathy, Factor Xa


The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality.

Author Biographies

N Padayachee, University of the Witwatersrand

Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, South Africa

N Schoeman

Hospital Pharmacist, Private Hospital Group, South Africa

N Schellack, University of Pretoria

Department of Pharmacology, University of Pretoria, South Africa

Focus on ...